三、2024 Version 3 版本在 2024 Version 2 版本的基础上做了如下调整: NSCL-18 ►新增脚注 II:FDA 批准的生物类似物是合适的替代选择。 参考文献 [1] NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Non-Small Cell Lung Cancer, Version 3.2024, March 12, 2024. 作者:黄玉庭;编辑...
1. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Small Cell Lung Cancer. Version 1.2024 2. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Small Cell Lung Cancer. Version 3.2023 撰写:Squid 审校:Babel 排版:Squid 执行:Squid 医脉通是专业的在线医生平台,“感知世界...
小细胞肺癌(SCLC, small cell lung cancer)约占所有肺癌患者的1/4,据统计全球每年有近25万的SCLC新发病例。由于其高侵袭性及易转移的特点,近2/3的患者在诊断初期就已为广泛期小细胞肺癌(ES-SCLC),从而失去了手术机会。化疗是ES-SCLC的标准治疗方案,但ES-SCLC中位总生存期(OS)始终未超过1年[2,3]。近期,...
参考文献: [1].NCCN Clinical Practice Guidelines in Oncology(NCCN Guidelines®)Non-Small Cell Lung Cancer.Version 1.2023. [2].NCCN Clinical Practice Guidelines in Oncology(NCCN Guidelines®)Non-Small Cell Lung Cancer.Version 1-6.2022. 医生站网页版上线啦! 无需下载便可浏览更多肿瘤资讯 责任编辑:...
National comprehensive cancer network(NCCN)clinical practice guidelines for non-small cell lung cancer. Wood DE. https://www.sogou.com/link?url=hed Jja ... D Pfister,K Ang,D Brizel - 《亚洲男性学杂志(英文版)》 被引量: 245发表: 2018年 National Comprehensive Cancer Network Clinical practice...
►新增脚注 II:FDA 批准的生物类似物是合适的替代选择。 参考文献 [1] NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Non-Small Cell Lung Cancer, Version 3.2024, March 12, 2024. 作者:黄玉庭;编辑:Bree 题图:图虫创意 投稿:sunjiamei@dxy.cn...
➤参考文献 40 新增:Solomon BJ, Drilon A, Lin JJ, et al. Repotrectinib in patients with NTRK fusion-positive advanced solid tumors, including non-small cell lung cancer: update from the phase 1/2 TRIDENT-1 trial. Ann Oncol, 2023; 34: S787-S788. ...
Felip E, Kuboki Y, et al. First-in-human dose-escalation trial of BI 764532, a delta-like ligand 3 (DLL3)/CD3 IgG-like T-cell engager in patients (pts) with DLL3-positive (DLL3+) small-cell lung cancer (SCLC) and neuroendocrine carcinoma (NEC). J Clin Oncol. 2023;41(suppl 16...
►新增参考文献 40:Solomon BJ, Drilon A, Lin JJ, et al. Repotrectinib in patients with NTRK fusion-positive advanced solid tumors, including non-small cell lung cancer: update from the phase 1/2 TRIDENT-1 trial. Ann Oncol. 2023;34:S787-S788. ...
此次指南更新一款ROS1、pan-TRK和ALK抑制剂瑞普替尼在全线治疗中的应用。早在2023年11月,其已在美国获批上市用于治疗ROS1阳性局部晚期或转移性NSCLC成人患者,诸多应用得益于I/II期TRIDENT-1研究更新的结果支持。 这项研究设计特别之处在于评估瑞普替尼用于ROS1 TKI初治人群(EXP-1队列)和ROS1 TKI经治人群(EXP-2...